Table 3.
Baseline Characteristics and Testing History of Secondary Cohort
| White | Black | Asian | P | |
|---|---|---|---|---|
| Subjects, n | 956 | 479 | 204 | |
| Female, n (%) | 526 (55) | 310 (65) | 122 (60) | 0.002a |
| Age (y), mean ± SD | 62.3 ± 15.4 | 59.9 ± 14.2 | 53.0 ± 15.7 | <0.001b |
| ADI, mean ± SD | 2.45 ± 1.98 | 3.61 ± 2.12 | 2.58 ± 1.80 | <0.001b |
| Baseline MD (dB), median (Q1, Q3) | −2.62 (−7.82, −0.58) | −4.31 (−10.66, −1.56) | −3.51 (−7.51, −1.01) | <0.001c |
| SLT, n (%) | 55 (5.6) | 20 (4.2) | 2 (1.0) | 0.011a |
| Glaucoma surgery, n (%) | 526 (55.0) | 310 (64.7) | 15 (7.4) | 0.319a |
| Visits per subject, mean ± SD | ||||
| Total (4 y) | 9.03 ± 8.99 | 9.04 ± 8.23 | 7.42 ± 6.96 | 0.042b |
| Pre-COVID (2 y) | 4.82 ± 5.06 | 5.10 ± 5.10 | 4.29 ± 3.90 | 0.149 |
| Mid-COVID (2 y) | 4.21 ± 6.04 | 3.94 ± 5.23 | 3.12 ± 4.75 | 0.044 |
| Mid-COVID – pre-COVID | −0.61 ± 6.58 | −1.16 ± 6.26 | −1.17 ± 5.21 | 0.217 |
| Frequency of OCT per subject, mean ± SD | ||||
| Total (4 y) | 2.80 ± 2.31 | 2.38 ± 1.90 | 2.11 ± 1.91 | <0.001b |
| Pre-COVID (2 y) | 1.39 ± 1.27 | 1.21 ± 1.09 | 1.14 ± 1.03 | 0.003 |
| Mid-COVID (2 y) | 1.42 ± 1.56 | 1.17 ± 1.29 | 0.97 ± 1.18 | <0.001 |
| Mid-COVID – pre-COVID | 0.03 ± 1.65 | −0.04 ± 1.46 | −0.17 ± 1.12 | 0.240 |
| Frequency of VFT per subject, mean ± SD | ||||
| Total (4 y) | 3.07 ± 2.09 | 2.74 ± 1.65 | 2.64 ± 1.65 | 0.001b |
| Pre-COVID (2 y) | 1.60 ± 1.11 | 1.46 ± 0.85 | 1.48 ± 0.80 | 0.027 |
| Mid-COVID (2 y) | 1.46 ± 1.48 | 1.28 ± 1.30 | 1.16 ± 1.19 | 0.004 |
| Mid-COVID – pre-COVID | −0.14 ± 1.57 | −0.19 ± 1.45 | −0.31 ± 1.18 | 0.310 |
| VFT/DoS ratio, mean ± SD | ||||
| Total (4 y) | 0.50 ± 0.29 | 0.46 ± 0.28 | 0.50 ± 0.27 | 0.047b |
| Pre-COVID (2 y) | 0.54 ± 0.32 | 0.48 ± 0.32 | 0.51 ± 0.29 | 0.004 |
| Mid-COVID (2 y) | 0.36 ± 0.36 | 0.31 ± 0.34 | 0.35 ± (0.36 | 0.107 |
| Mid-COVID – pre-COVID | −0.18 ± 0.45 | −0.16 ± 0.44 | −0.16 ± 0.45 | 0.735 |
a
Pearson's χ2 test.
b
ANOVA.
c
Kruskal–Wallis rank sum test.